Account Login
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biovie Inc (NQ: BIVI )

37.17 +7.23 (+24.15%)
Streaming Delayed Price Updated: 3:14 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Biovie Inc

BioVie Interview to Air on Bloomberg International on the RedChip Money Report
From GlobeNewswire News Releases
BioVie to Participate in B. Riley Securities Liver Disease Therapeutics Day on October 29, 2020
From GlobeNewswire News Releases
BioVie Announces Closing of Public Offering of Common Stock
Includes Full Exercise of Underwriters’ Overallotment Option 
From GlobeNewswire News Releases
BioVie to Present at Oppenheimer Fall Healthcare Life Sciences & Medtech Summit
From ACCESSWIRE
Highly Accomplished Executives Join BioVie’s Board of Directors
From GlobeNewswire News Releases
BioVie Advances the BIV201 Clinical Program and Prefilled Syringe
From GlobeNewswire News Releases
BioVie Submits Protocol for Phase 2b/3 Refractory Ascites Study to FDA
From ACCESSWIRE
BriaCell Appoints Richard J. Berman to Board of Directors
From GlobeNewswire News Releases
BioVie Achieves Primary Objectives in Phase 2a Clinical Trial of BIV201 in Refractory Ascites
BioVie Inc. (OTCQB: BIVI) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for liver disease, today announced top-line results for its Phase 2a clinical trial of... 
From GlobeNewswire News Releases
BioVie to Present at ThinkEquity Conference in NYC on May 2nd
BioVie Inc. (OTCQB: BIVI) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for liver disease, announced that Mr. Terren Peizer, the Company’s Chairman and CEO, is... 
From GlobeNewswire News Releases
BioVie Completes Patient Enrollment for its Phase 2a Clinical Trial of BIV201 in Refractory Ascites
BioVie Inc. (OTCQB: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for liver disease, announced today that it has completed enrollment in a Phase 2a... 
From GlobeNewswire News Releases
BioVie’s New Drug Candidate BIV201 Receives FDA Orphan Drug Designation for the Treatment of Hepatorenal Syndrome (HRS)
From ACCESSWIRE
Veterinary Vaccines Market Opportunity by 2026 : Merial, Zoetis, Elanco, Merck & Co. Inc., Boehringer Ingelheim GmbH)(BIVI), Bayer Pharma AG
Valley Cottage, NY -- (SBWIRE) -- 10/30/2018 -- Increasing focus on maintaining the reproductive health of livestock is expected to generate significant demand for livestock veterinary vaccines, finds... 
From SBWire - Latest Press Releases
BioVie Inc. (OTCQB:BIVI) Attains Milestone
Company Reaches 50% Patient Enrollment in Phase 2a Clinical Trial of BIV201 for Refractory Ascites 
From GlobeNewswire News Releases
BioVie to Present at The MicroCap Conference in New York on April 9th
BioVie Inc. (OTCQB:BIVI), a clinical-stage company focused on the development and commercialization of innovative drug therapies for liver disease, announced today that it will participate in The... 
From GlobeNewswire News Releases
BioVie Responds to Japan Patent Office and Comments on Recent Stock Price Decline
BioVie Inc. (OTCQB:BIVI), a clinical-stage company focused on the development and commercialization of innovative drug therapies for liver disease, announced today that it submitted a response to... 
From GlobeNewswire News Releases
BioVie Receives FDA Fast Track Designation for BIV201 for the Treatment of Refractory Ascites Due to Advanced Liver Cirrhosis
From Marketwired News Releases
BioVie Announces Second Patient Dosed with BIV201 in Phase 2a Clinical Trial; First Patient Completes 28-day Treatment Regimen
From Marketwired News Releases
Accomplished BioPharma Executive Mina Sooch Joins BioVie Board of Directors and Purchases Company Stock
From Marketwired News Releases
Michael Sherman Joins BioVie Board of Directors and Purchases Company Stock
From Marketwired News Releases
BioVie Announces First Patient Dosed with BIV201 in Phase 2a Clinical Trial for Refractory Ascites due to Liver Cirrhosis
From Marketwired News Releases
Rich Wieland Joins BioVie Management Team as Chief Financial Officer
From Marketwired News Releases
CORRECTION - BioVie Inc.
From Marketwired News Releases
First Patent Enrolled in BioVie Phase 2a Clinical Trial of BIV201 for Ascites
From Marketwired News Releases
BioVie Reports Fiscal Year 2017 Financial Results and Clinical Development Progress
From Marketwired News Releases
BioVie Files Patent Application in Japan for BIV201 for the Treatment of Ascites Due to Liver Cirrhosis
From Marketwired News Releases
BioVie Inc. to Present at the 7th Annual LD Micro Invitational
From ACCESSWIRE
BioVie Announces Issuance of US Patent Covering BIV201 for the Treatment of Ascites Due to Liver Cirrhosis
From Marketwired News Releases
Distinguished BioPharma Executive Hari Kumar Joins BioVie Board of Directors and Purchases Company Stock
From Marketwired News Releases
BioVie Signs Cooperative Research and Development Agreement (CRADA) to Conduct a Phase 2a Clinical Trial of BIV201 in Refractory Ascites Patients
From Marketwired News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.